OTCMKTS:NRNVF Nordic Nanovector ASA (NRNVF) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free NRNVF Stock Alerts $1.64 0.00 (0.00%) (As of 10/18/2021) Add Compare Share Share Today's Range$1.64▼$1.6450-Day Range$1.64▼$1.6452-Week Range$1.64▼$1.64VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Nordic Nanovector ASA alerts: Email Address Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Nordic Nanovector ASANordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway and internationally. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. Nordic Nanovector ASA has collaboration agreements with Paul Scherrer Institute; Areva Med; LegoChem Bio; and Heidelberg Pharma. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.Read More NRNVF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRNVF Stock News HeadlinesDecember 9, 2022 | prnewswire.comNordic Nanovector update following shareholder vote against proposed merger with APIM TherapeuticsNovember 23, 2022 | prnewswire.comNordic Nanovector: Invitation to webcast regarding proposed merger with APIM TherapeuticsApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.August 31, 2022 | prnewswire.comNordic Nanovector ASA Results for the Second Quarter and First Half 2022August 26, 2022 | prnewswire.comNordic Nanovector consolidates senior leadership team and restructures to conserve resources as it explores strategic optionsMarch 11, 2022 | prnewswire.comNordic Nanovector ASA - allocation of PSUsFebruary 14, 2022 | prnewswire.comNordic Nanovector ASA: Extraordinary general meeting heldJanuary 7, 2022 | prnewswire.comNordic Nanovector Provides update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular LymphomaApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.December 23, 2021 | prnewswire.comNordic Nanovector ASA: Financial Calendar for 2022November 29, 2021 | prnewswire.comNordic Nanovector ASA: R&D Day to be virtual via live webcast onlyNovember 12, 2021 | prnewswire.comNordic Nanovector ASA: Invitation to Third Quarter 2021 Results Presentation and WebcastNovember 9, 2021 | prnewswire.comNordic Nanovector supports The Health Policy Partnership's initiative to improve appropriate readiness for radioligand therapy (radioimmunotherapy) in lymphomaOctober 19, 2021 | prnewswire.comNordic Nanovector enters research collaboration with the University of Pennsylvania to generate a novel CD37-targeting CAR-T cell approachAugust 20, 2021 | prnewswire.comNordic Nanovector ASA: Invitation to Second Quarter and First Half 2021 Results Presentation WebcastSee More Headlines Receive NRNVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nordic Nanovector ASA and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:NRNVF CUSIPN/A CIKN/A Webwww.nordicnanovector.com Phone47 22 18 33 01FaxN/AEmployees39Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMs. Malene Brondberg (Age 48)Chief Financial Officer Comp: $484.24kDr. Marco Renoldi (Age 64)Chief Operating Officer Comp: $537.62kDr. Lars Nieba Ph.D. (Age 53)Chief Technology Officer Comp: $575.23kDr. Jostein Dahle (Age 48)Chief Scientific Officer Comp: $268.75kMs. Rosemarie Corrigan (Age 56)Chief Quality Officer Comp: $407.39kDr. Christine Wilkinson Blanc M.D.M.Sc., Chief Medical OfficerDr. Gabriele Elbl (Age 60)VP Global Regulatory Affairs Comp: $486.46kMr. Peter L. BraunChief Exec. OfficerMr. Fredrik HaavindHead of Legal & ComplianceMs. Maureen DeehanHead of Corp. Devel. & StrategyMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors NRNVF Stock Analysis - Frequently Asked Questions How have NRNVF shares performed in 2024? Nordic Nanovector ASA's stock was trading at $1.6383 at the beginning of 2024. Since then, NRNVF stock has increased by 0.0% and is now trading at $1.6383. View the best growth stocks for 2024 here. How do I buy shares of Nordic Nanovector ASA? Shares of NRNVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NRNVF) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nordic Nanovector ASA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
